<unk>  is indicated for adjuvant treatment of adults with HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature; and it is indicated in combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer.
Trastuzumab/hyaluronidase
Trastuzumab emtansine
Pertuzumab/trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Bortezomib/dexamethasone
Trifluridine/tipiracil
Daratumumab/hyaluronidase
Decitabine/cedazuridine